Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG)

Öz:

Objective: Peripheral T-cell lymphomas (PTCLs) are an uncommon and quite heterogeneous group of disorders, representing only 10%-15% of all non-Hodgkin lymphomas. Although both molecular and clinical studies have increased in recent years, we still have little knowledge regarding real-life practice with PTCLs. In this study, we aimed to investigate the clinical characteristics and treatment outcomes of a large population-based cohort of patients presenting with systemic non-cutaneous PTCL. Materials and Methods: We conducted a multicenter retrospective analysis of 190 patients consecutively diagnosed and treated with non-cutaneous PTCLs between 2008 and 2016. Results: Considering all first-line treatment combinations, the overall response rate was 65.9% with 49.4% complete remission (n=81) and 16.5% partial response (n=27). The 5-year overall survival and event- free survival rates were significantly different between the transplant and non-transplant groups (p<0.01, and p=0.033, respectively). Conclusion: The retrospective analysis of a large volume of real-life data on the Turkish experience regarding non-cutaneous PTCL patients showed consistent results compared to other unselected PTCL cohorts with some minor differences in terms of survival and transplantation outcomes. The long-term outcome of patients who receive autologous hematopoietic cell transplantation as part of upfront consolidation or salvage therapy is favorable compared to patients who are unable to receive high-dose therapy.

Anahtar Kelime:

Non-kutanöz Periferik T-hücreli Lenfomalarda Klinik Özellikler ve Tedavi Sonuçlarına ilişkin Gerçek Yaşam Deneyimi:Türk Hematoloji Araştırma ve Eğitim Grubunun Çok Merkezli Çalışması

Öz:

Amaç: Periferik T-hücreli lenfomalar (PTHL) nadir görülen, oldukça heterojen bir grup hastalıktır ve tüm non-Hodgkin lenfomaların sadece %10-15’ini oluşturur. Son yıllarda hem moleküler hem de klinik çalışmalar artmış olsa da PTHL’ler üzerindeki gerçek yaşam verileri hakkında hala çok az bilgiye sahibiz. Bu çalışmada, sistemik, kutanöz olmayan PTHL hastaları içeren geniş popülasyon tabanlı hasta grubunun klinik özellikleri ve tedavi sonuçlarını araştırmayı amaçladık. Gereç ve Yöntemler: 2008 ve 2016 yılları arasında kutanöz olmayan PTHL tanısı ile tedavi edilen 190 ardışık hastanın geriye dönük analizini gerçekleştirdik. Bulgular: Tüm birinci basamak tedavi kombinasyonları dikkate alındığında, genel yanıt oranı; tam remisyon (n=81) %49,4 ve kısmi yanıt (n=27) %16,5 olmak üzere %65,9 saptandı. Beş yıllık genel ve olaysız sağkalım oranları, transplant ve transplant olmayan gruplar arasında önemli ölçüde farklıydı (sırasıyla, p<0,01 ve p=0,033). Sonuç: Kutanöz olmayan PTHL hastalarıyla ilgili geniş geriye dönük gerçek yaşam veri analizini kapsayan Türkiye deneyimi, sağkalım ve transplantasyon sonuçları açısından bazı küçük farklar içerse de seçilmemiş diğer PTHL serileriyle benzer sonuçlar göstermiştir. Planlı veya kurtarma tedavisinin bir parçası olarak otolog hematopoietik hücre transplantasyonu olan hastaların uzun dönem sonuçları, yüksek doz tedavi almayan hastalara kıyasla daha iyiydi.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1.Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-4130.
2. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15:1467-1475.
3. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, Savage KJ. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013;31:1970-1976.
4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, International Agency for Research on Cancer, 2017.
5. Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Groupe d’Etude des Lymphomes Agressives (GELA). Ann Oncol 1990;1:45-50.
6. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011;117:6756-6767.
7. Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T cell lymphoma incidence and survival in the United States. J Clin Oncol 2016;34:963-971.
8. Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 2014;124:1570-1577.
9. Pedersen MB, Hamilton-Dutoit SJ, Bendix K, Møller MB, Nørgaard P, Johansen P, Ralfkiaer E, Brown Pde N, Hansen PB, Jensen BA, Madsen J, Schöllkopf C, d’Amore F. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T cell lymphomas from the Danish Lymphoma Registry. Hematol Oncol 2015;33:120-128.
10. Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, Prochazka V, Pytlik R, Pirnos J, Duras J, Mocikova H, Bortlicek Z, Kopalova N, Mayer J, Trneny M. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol 2019;98:1961-1972.
11. Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM; Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project. Gene expression signatures delineate and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014;123:2915-2923.
12. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014;124:1473-1480.
13. Pedersen MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, Bedroske PP, Luoma IM, Sattler CA, Boddicker RL, Bennani NN, Nørgaard P, Møller MB, Steiniche T, d’Amore F, Feldman AL. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood 2017;130:554-557.
14. Siaghani PJ, Song JY. Updates of peripheral T cell lymphomas based on the 2017 WHO classification. Curr Hematol Malig Rep 2018;13:25-36.
15. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM; International Peripheral T-cell Lymphoma Project. Peripheral Tcell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T cell Lymphoma Project. Blood 2011;117:3402- 3408.
16. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Peripheral T cell lymphoma in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 2014;25:2211-2217.
17. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:3418-3425.
18. Tse E, Kwong YL. Diagnosis and management of extranodal NK/T cell lymphoma nasal type. Expert Rev Hematol 2016;9:861-871.
19. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533- 1538.
20. d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. Up-front autologous stem-cell transplantation in peripheral T cell lymphoma: NLG-T-01. J Clin Oncol 2012;30:3093-3099.
21. d’Amore F, Relander T, Lauritzsen G, Jantunen E, Hagberg H, Holte H, Österborg A, Brown PD, Kuittinen O, Erlanson M, Østenstad B, Fagerli U, Anderson H, Liestøl K, Toldbod H. Ten years median follow-up of the Nordic NLG-T-01 trial on CHOEP and upfront autologous transplantation in peripheral T cell lymphomas. Hematol Oncol 2015;33(Suppl 1):139 (abstract).
22. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d’Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2017;23:1826-1838.
23. Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, Giralt SA, LeMaistre CF, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Veys PA, Carpenter PA, Hamadani M. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 2020;26:1247-1256.
24. Rodríguez J, Caballero MD, Gutiérrez A, Marín J, Lahuerta JJ, Sureda A, Carreras E, León A, Arranz R, Fernández de Sevilla A, Zuazu J, García- Laraña J, Rifon J, Varela R, Gandarillas M, SanMiguel J, Conde E. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003;14:1768-1775.
25. Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, Slack GW, Smedby KE, Ansell SM, Link BK, Cerhan JR, Relander T, Savage KJ, Feldman AL. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol 2017;35:4019-4026.

APA	Kayıkçı Ö, Mehtap Ö, Sari I, Demirkan F, Beyan C, Cetin G, vural f, Yilmaz M, Öztürk E, AKPINAR S, Eser B, Gunduz M, Buyukasik Y, Payzin B, YILDIRIM R, Doğu M, Ozkan H, Kelkitli E, tekgunduz e (2022). Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG). , 170 - 177. 10.4274/tjh.galenos.2022.2022.0052
Chicago	Kayıkçı Ömür,Mehtap Özgür,Sari Ismail,Demirkan Fatih,Beyan Cengiz,Cetin Guven,vural filiz,Yilmaz Mehmet,Öztürk Erman,AKPINAR SEVAL,Eser Bülent,Gunduz Mehmet,Buyukasik Yahya,Payzin Bahriye,YILDIRIM Rahsan,Doğu Mehmet Hilmi,Ozkan Hasan Atilla,Kelkitli Engin,tekgunduz emre Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG). (2022): 170 - 177. 10.4274/tjh.galenos.2022.2022.0052
MLA	Kayıkçı Ömür,Mehtap Özgür,Sari Ismail,Demirkan Fatih,Beyan Cengiz,Cetin Guven,vural filiz,Yilmaz Mehmet,Öztürk Erman,AKPINAR SEVAL,Eser Bülent,Gunduz Mehmet,Buyukasik Yahya,Payzin Bahriye,YILDIRIM Rahsan,Doğu Mehmet Hilmi,Ozkan Hasan Atilla,Kelkitli Engin,tekgunduz emre Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG). , 2022, ss.170 - 177. 10.4274/tjh.galenos.2022.2022.0052
AMA	Kayıkçı Ö,Mehtap Ö,Sari I,Demirkan F,Beyan C,Cetin G,vural f,Yilmaz M,Öztürk E,AKPINAR S,Eser B,Gunduz M,Buyukasik Y,Payzin B,YILDIRIM R,Doğu M,Ozkan H,Kelkitli E,tekgunduz e Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG). . 2022; 170 - 177. 10.4274/tjh.galenos.2022.2022.0052
Vancouver	Kayıkçı Ö,Mehtap Ö,Sari I,Demirkan F,Beyan C,Cetin G,vural f,Yilmaz M,Öztürk E,AKPINAR S,Eser B,Gunduz M,Buyukasik Y,Payzin B,YILDIRIM R,Doğu M,Ozkan H,Kelkitli E,tekgunduz e Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG). . 2022; 170 - 177. 10.4274/tjh.galenos.2022.2022.0052
IEEE	Kayıkçı Ö,Mehtap Ö,Sari I,Demirkan F,Beyan C,Cetin G,vural f,Yilmaz M,Öztürk E,AKPINAR S,Eser B,Gunduz M,Buyukasik Y,Payzin B,YILDIRIM R,Doğu M,Ozkan H,Kelkitli E,tekgunduz e "Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG)." , ss.170 - 177, 2022. 10.4274/tjh.galenos.2022.2022.0052
ISNAD	Kayıkçı, Ömür vd. "Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG)". (2022), 170-177. https://doi.org/10.4274/tjh.galenos.2022.2022.0052

APA	Kayıkçı Ö, Mehtap Ö, Sari I, Demirkan F, Beyan C, Cetin G, vural f, Yilmaz M, Öztürk E, AKPINAR S, Eser B, Gunduz M, Buyukasik Y, Payzin B, YILDIRIM R, Doğu M, Ozkan H, Kelkitli E, tekgunduz e (2022). Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG). Turkish Journal of Hematology, 39(3), 170 - 177. 10.4274/tjh.galenos.2022.2022.0052
Chicago	Kayıkçı Ömür,Mehtap Özgür,Sari Ismail,Demirkan Fatih,Beyan Cengiz,Cetin Guven,vural filiz,Yilmaz Mehmet,Öztürk Erman,AKPINAR SEVAL,Eser Bülent,Gunduz Mehmet,Buyukasik Yahya,Payzin Bahriye,YILDIRIM Rahsan,Doğu Mehmet Hilmi,Ozkan Hasan Atilla,Kelkitli Engin,tekgunduz emre Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG). Turkish Journal of Hematology 39, no.3 (2022): 170 - 177. 10.4274/tjh.galenos.2022.2022.0052
MLA	Kayıkçı Ömür,Mehtap Özgür,Sari Ismail,Demirkan Fatih,Beyan Cengiz,Cetin Guven,vural filiz,Yilmaz Mehmet,Öztürk Erman,AKPINAR SEVAL,Eser Bülent,Gunduz Mehmet,Buyukasik Yahya,Payzin Bahriye,YILDIRIM Rahsan,Doğu Mehmet Hilmi,Ozkan Hasan Atilla,Kelkitli Engin,tekgunduz emre Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG). Turkish Journal of Hematology, vol.39, no.3, 2022, ss.170 - 177. 10.4274/tjh.galenos.2022.2022.0052
AMA	Kayıkçı Ö,Mehtap Ö,Sari I,Demirkan F,Beyan C,Cetin G,vural f,Yilmaz M,Öztürk E,AKPINAR S,Eser B,Gunduz M,Buyukasik Y,Payzin B,YILDIRIM R,Doğu M,Ozkan H,Kelkitli E,tekgunduz e Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG). Turkish Journal of Hematology. 2022; 39(3): 170 - 177. 10.4274/tjh.galenos.2022.2022.0052
Vancouver	Kayıkçı Ö,Mehtap Ö,Sari I,Demirkan F,Beyan C,Cetin G,vural f,Yilmaz M,Öztürk E,AKPINAR S,Eser B,Gunduz M,Buyukasik Y,Payzin B,YILDIRIM R,Doğu M,Ozkan H,Kelkitli E,tekgunduz e Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG). Turkish Journal of Hematology. 2022; 39(3): 170 - 177. 10.4274/tjh.galenos.2022.2022.0052
IEEE	Kayıkçı Ö,Mehtap Ö,Sari I,Demirkan F,Beyan C,Cetin G,vural f,Yilmaz M,Öztürk E,AKPINAR S,Eser B,Gunduz M,Buyukasik Y,Payzin B,YILDIRIM R,Doğu M,Ozkan H,Kelkitli E,tekgunduz e "Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG)." Turkish Journal of Hematology, 39, ss.170 - 177, 2022. 10.4274/tjh.galenos.2022.2022.0052
ISNAD	Kayıkçı, Ömür vd. "Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG)". Turkish Journal of Hematology 39/3 (2022), 170-177. https://doi.org/10.4274/tjh.galenos.2022.2022.0052